Breakthrough drug trial offers hope for rare blood disorder patients in china
NCT ID NCT05876351
Summary
This study tested whether the drug eculizumab can control atypical hemolytic uremic syndrome (aHUS), a rare and serious blood disorder that can damage kidneys. The trial included 25 Chinese children and adults who had never received similar complement inhibitor treatments. Participants received eculizumab for 26 weeks while researchers monitored their blood counts, kidney function, and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL HEMOLYTIC UREMIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100034, China
-
Research Site
Beijing, 100045, China
-
Research Site
Changsha, 410007, China
-
Research Site
Qingdao, 110016, China
-
Research Site
Taiyuan, 030012, China
-
Research Site
Wuhan, 430030, China
Conditions
Explore the condition pages connected to this study.